Aldesleukin

Drug Profile

Aldesleukin

Alternative Names: Chiron IL-2; IL-2; IL-2 - Chiron; interleukin-2 - Chiron; Macrolin™; Proleukin; Recombinant IL-2; Recombinant IL-2 - Chiron; T cell growth factor

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Chiron
  • Developer Hyup Jin Corporation; Ligand Pharmaceuticals; Novartis
  • Class Antineoplastics; Interleukins; Recombinant proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Non-Hodgkin's lymphoma; Malignant melanoma; Immunodeficiency disorders; Renal cell carcinoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Malignant melanoma; Renal cell carcinoma
  • Discontinued HIV-1 infections; Non-Hodgkin's lymphoma

Most Recent Events

  • 01 Sep 2016 Prometheus Laboratories initiates a phase II trial for Malignant melanoma (Metastatic disease; Late-stage disease, Second-line or greater therapy) in USA (NCT02796352)
  • 15 Jun 2016 Prometheus Laboratories plans a phase II trial for Malignant melanoma (Metastatic disease; Late-stage disease, Second-line or greater therapy) in USA (NCT02796352)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top